News

Updated on Feb 18, 2025 Share

Brandon McNaughton, CEO of Akadeum Life Sciences Inc., recently shared insights with BioWorld about the company’s Alerion™ Microbubble Cell Separation System, set to transform cell therapy. Akadeum, established in 2014, has developed a unique microbubble-based cell separation technology. The Alerion™ Microbubble Cell Separation System promises to overcome the limitations of existing methods, offering better workflows, scalability, and productivity. The Alerion™ system uses a two-chamber consumable, allowing microbubbles to adhere to …

Updated on Nov 1, 2024 Share

Akadeum Life Sciences CEO and Co-Founder Brandon McNaughton‘s recent article, “Microbubbles: The Unlikely Key to Providing Accessible and Effective Cancer Treatments,” has been published by Onco’Zine. Onco’Zine informs and supports healthcare professionals, academics, and pharmaceutical experts in oncology, covering the latest research and developments in the field. McNaughton discusses how Akadeum’s microbubble technology can revolutionize T cell isolation, reducing costs and improving the efficacy of cell therapies like CAR T …

Updated on Feb 18, 2025 Share

Akadeum Life Sciences CEO and Co-Founder Brandon McNaughton’s article “CAR T Cell Therapy Is Offering Life-lines to Cancer Patients, but Only to Those Who Can Afford It” was recently published by Medical Device News Magazine. Medical Device News Magazine is a US-based publication that aims to inform and educate medical specialists on breaking device news across various specialties, including general surgery, neurosurgery, artificial intelligence, FDA updates, diagnostic modalities, and executive …

Updated on Feb 18, 2025 Share

Akadeum Life Sciences CEO and Co-Founder Brandon McNaughton’s article “Opinion: Cell Therapy Cancer Treatments Are Coming. Now to Make Them More Accessible.” was recently published by BioSpace. BioSpace is a tier 1 life sciences trade publication renowned for delivering the latest industry news and expert analysis. Cell and gene therapies like CAR T cell treatment offer immense promise for cancer, but current high costs limit accessibility. Companies aim to reduce …

Updated on Nov 22, 2024 Share

This revolutionary instrument marks an important step in bringing the performance advantages of our products into clinical manufacturing workflows.  ANN ARBOR, MI, Oct. 10, 2023 – Akadeum Life Sciences, the global leaders in buoyancy-based cell separation technology, have announced today the preview of their Alerion™cell separation system. The instrument will provide a closed system for separating T cells from a leukopak using Akadeum’s revolutionary Buoyancy Activated Cell Sorting (BACS™) microbubble …

Updated on Nov 4, 2024 Share

These exceptional companies help make the Ann Arbor area a great place to live, work and play. ANN ARBOR September 26, 2023 — Akadeum Life Sciences has been selected for the 2023 Best of Ann Arbor Award in the Biotechnology Company category by the Ann Arbor Award Program. Each year, the Ann Arbor Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and …

Updated on Nov 4, 2024 Share

Ann Arbor, MI, September 12, 2023 – Akadeum Life Sciences, the global leader in buoyancy-based cell separation, have today announced Jim Militello as their new Chief Financial Officer (CFO), effective September 12, 2023. Jim will play a key role in overseeing the fundraising, financial analysis and strategic planning of Akadeum as it continues its rapid growth in a market set to surpass $11.6bn by 2030. With a career spanning over …

Updated on Dec 3, 2024 Share

The gentle microbubble floatation process not only produces healthier cells, but is also a quicker, more efficient, and cost effective solution compared to outdated legacy methods. ANN ARBOR, Mich., Sept. 7, 2023 – Akadeum Life Sciences, the global leaders in buoyancy-based cell separation technology, have today announced the release of their ‘Human T Cell Activation & Expansion Kit’ with Buoyancy Activated Cell Sorting (BACS) microbubbles. The first-of-its-kind kit is designed …

Updated on Nov 4, 2024 Share

Brandon McNaughton, Founder and CEO of Akadeum Life Sciences, recently conducted an interview with Grant Playter, Associate Editor, now featured on the PharmTech and BioPharm International websites. In this interview, McNaughton discussed Akadeum’s groundbreaking microbubble separation technology and its role in the evolving landscape of cell and gene therapies. McNaughton’s extensive experience, including over 15 years in magnetic beads and nanoparticles, and his background in startup ventures and venture capital, …

Updated on Nov 4, 2024 Share

Brandon McNaughton, CEO and co-founder of Akadeum Life Sciences, was recently highlighted with other influential Michigan-based thought leaders in a Purpose Job’s recent article celebrating Michigan Founders Fund’s 100-member milestone. The Michigan Founders Fund (MFF) recently celebrated reaching over 100 members in its statewide venture network supporting high-growth entrepreneurs. MFF members pledge 1% of equity to a fund for grantmaking focused on underrepresented founders, local talent development, and racial equity. …